

**Author Index for 1987**

Aalbers, C. 20:239, 22:127  
Abrams, R. 20:57  
Aceti, F. 20:207  
Alessi, N.E. 20:275  
Almay, B.G.L. 22:179  
Amiri, Z. 21:221  
Amsterdam, J.D. 20:325, 21:189  
Angrist, B. 21:185  
Ansseau, M. 22:193  
Apelt, S. 22:303  
Arató, M. 21:355  
Arger, P. 21:189  
Aryan, Z.S. 20:307  
Asai, M. 21:49  
Asnis, G. 20:79  
  
Balon, R. 21:359, 22:37, 22:263  
Barchas, J.D. 21:1, 22:21  
Barksdale, C. 22:117  
Bartkó, G. 22:221  
Bartko, J.J. 20:165  
Baumgartner, R. 20:33  
Baxter, L.R., Jr. 21:237  
Bellodi, L. 21:293  
Benjamin, E. 22:257  
Benkert, O. 20:177  
Berchou, R. 21:359  
Berenbaum, S.A. 20:57  
Berg, L. 21:55  
Berger, P.A. 20:47, 21:1, 22:21, 22:29  
Berman, N. 20:1  
Berman, S.R. 21:95  
Berrettini, W.H. 22:141  
Bigler, E.D. 22:91  
Bochnik, H.J. 22:275  
Boronow, J. 22:91  
Borst, U. 22:331  
Boulenger, J.-P. 21:247  
Brambilla, F. 20:19  
Breslau, N. 20:285  
Brewerton, T.D. 21:213  
Brochet, D.M. 21:267  
Brody, D. 21:185  
Brown, A. 22:261  
Bruza, D. 22:261  
Burns, E.M. 20:165, 22:229  
Burrows, G.D. 22:43  
Butters, N. 21:357  
Byron, J.P., Jr. 20:261  
  
Calderon, M. 20:33  
Calil, H.M. 21:337  
Campeas, R. 22:89  
  
Candolfi, C. 20:19  
Carpenter, W.T., Jr. 22:319  
Carstens, M.E. 20:239, 22:127  
Casper, R.C. 20:249  
Cavagnini, F. 20:19  
Cazzullo, C.L. 21:293  
Cerfontaine, J.-L. 22:193  
Chalton, D.O. 20:239, 22:127  
Chamberlain, K.G. 20:199  
Channabasavanna, S.M. 21:349  
Charney, D.S. 21:33  
Cherek, D.R. 21:257  
Chrousos, G.P. 20:229  
Climko, R. 20:261  
Coccaro, E.F. 22:257  
Codd, E.E. 22:61  
Coffman, J.A. 22:229  
Cohen, B.M. 20:107, 20:299  
Cohen, M.R. 21:43  
Cohen, R. 22:331  
Cohn, B.S. 21:205  
Cole, J.O. 20:143, 20:155  
Comess, K.A. 20:13  
Cooper, T.B. 20:313  
Coromilas, J. 22:341  
Coryell, W. 20:265  
Coulter, M.E. 22:149  
Cowley, D.S. 21:169  
Csernansky, J.G. 20:47  
  
Dackis, C.A. 20:261  
Dager, S.R. 20:13, 21:169  
Davidson, M. 20:307  
Davies, B.M. 22:213  
Davies, M. 22:341  
Davis, G.C. 20:285  
Davis, J.M. 20:165, 22:265  
Davis, K.L. 20:307, 22:257  
Dawson, G. 22:117  
Delis, D.C. 21:357  
DeLisi, L.E. 20:69  
Demeter, E. 21:355  
Demisch, L. 22:275  
De Ruyter, M. 21:323  
de Villiers, A.S. 22:127  
Dillon, D.J. 20:97, 21:205  
Dilsaver, S.C. 20:275  
di Rosa, M. 21:293  
Dixon, K.N. 20:189  
Dobben, G.D. 20:165  
Doran, A.R. 21:23  
Dose, M. 22:303  
Drinka, P.J. 21:199

Droba, M. 20:325  
 Dugger, D. 21:123  
 Dunner, D.L. 21:13, 21:169  
 Dupont, R.M. 21:357  
 Dysken, M. 20:165  
 Ebstein, R.P. 21:221  
 Edell, W.S. 20:129  
 Emrich, H.M. 22:303  
 Engelbrecht, A.H. 20:239  
 Erlenmeyer-Kimling, L. 22:159  
 Fairbanks, L. 21:237  
 Falus, A. 21:355  
 Faull, K.F. 21:1, 22:21  
 Fiume, S. 20:207  
 Foa, E.B. 21:123  
 Foreman, P.J. 22:69  
 Fraioli, F. 20:207  
 Frajese, G. 20:207  
 Franck, G. 22:193  
 Frazer, A. 20:1  
 French, M.A. 20:199  
 Frick, K. 20:117  
 Friedhoff, A.J. 21:185  
 Fuentenebro, F. 22:283  
 Fujita, H. 21:285, 22:81  
 Fulgham, J.R. 21:359  
 Fyer, A.J. 20:97, 21:23, 21:205, 22:341  
 Gagiano, C.A. 20:239, 22:127  
 Galderisi, S. 21:137  
 Gambini, O. 21:293  
 Garbutt, J.C. 21:307  
 Garnett, D. 21:89  
 Garvey, M.J. 20:183  
 Gebhart, P. 22:275  
 Geenen, V. 22:193  
 Gelenberg, A.J. 20:107  
 George, D.T. 21:213  
 Georgi, K. 22:275  
 Gerbaldo, H. 22:275  
 Gershon, E.S. 20:69  
 Gillin, J.C. 20:181, 21:357  
 Giordani, A.B. 20:307  
 Glenn, M. 21:307  
 Glover, V. 22:111  
 Gold, M.S. 20:261  
 Gold, P.W. 20:229  
 Goldin, L.R. 20:69  
 Goldstein, S. 20:79  
 Goodman, S.I. 22:291  
 Gorman, J.M. 20:97, 21:23, 21:205, 22:371  
 Gottesman, I.I. 22:159  
 Grabowski, J. 22:261  
 Graziosi, S. 20:207  
 Griez, E.J.L. 20:87  
 Gross, H.S. 22:69  
 Grossman, A. 22:207  
 Guthrie, S. 21:161  
 Gutman, R. 21:43  
 Guze, B.H. 21:237  
 Halbreich, U. 20:79  
 Hama, Y. 21:285  
 Hanin, I. 22:49  
 Harrison, W. 21:9  
 Heinrichs, D.W. 22:319  
 Heninger, G.R. 21:33  
 Herczeg, I. 22:221  
 Hesselink, J.R. 21:357  
 Himmelhoch, J.M. 22:49  
 Hobin, P. 21:323  
 Hoch, C.C. 21:95, 21:111  
 Hollander, E. 22:89  
 Hollifield, M. 21:313  
 Holsboer, F. 20:83, 20:177  
 Houck, P.A. 21:95  
 Hsiao, J.K. 22:69  
 Huggins, T. 22:11  
 Hyde, T.S. 21:169  
 Innis, R.B. 21:33  
 Invitti, C. 20:19  
 Iio, M. 21:285, 22:81  
 Irwin, M.R. 20:181, 22:283  
 Ishii, T. 21:285, 22:81  
 Jacobsen, F.M. 22:1  
 James, S.P. 21:89  
 Janicak, P.G. 22:265  
 Javaid, J.I. 20:249  
 Jernigan, T.L. 21:357  
 Jimerson, D.C. 21:213  
 Joffe, R.T. 21:71  
 Jordan, R.C. 21:63  
 Judd, F.K. 22:43  
 Kaku, H. 21:229  
 Kalin, N.H. 22:117  
 Kanba, S. 21:49  
 Kang, B.J. 20:79  
 Kärkkäinen, J. 21:151  
 Kartakis, D. 20:221  
 Kathol, M.H. 22:229  
 Katon, W.J. 21:313  
 Kaufmann, C.A. 20:337  
 Kelly, T.H. 21:257  
 Kemali, D. 21:137  
 Kempler, S. 22:311

Khan, A. 20:13  
 Khanna, S. 21:349  
 Kimber, N.M. 22:43  
 King, R.J. 21:1, 22:29  
 Kishimoto, H. 21:285, 22:81  
 Kitamura, T. 21:49  
 Klar, H. 22:257  
 Klein, D.F. 20:97, 21:23, 21:205, 22:341  
 Kleinman, J.E. 22:291  
 Knopf, S. 22:49  
 Knowles, J.B. 22:149  
 Korpi, E.R. 20:337, 22:291  
 Koslow, S.H. 20:1  
 Kozak, M.J. 21:123  
 Kruckeberg, T.W. 22:229  
 Kupfer, D.J. 21:95, 21:111  
 Kuwahara, H. 21:285, 22:81  
 Laatikainen, T. 21:151  
 Lacoste, V. 21:181  
 Lajtha, A. 20:313  
 Lampertico, M. 20:19  
 Langlais, P.J. 20:143, 20:155  
 Legros, J.-J. 22:193  
 Lerbinger, J.E. 20:143, 20:155  
 Lerer, B. 21:221  
 Levin, A.P. 21:23  
 Levy, A.B. 20:189  
 Liebowitz, M.R. 20:97, 21:23, 21:205,  
     22:89, 22:341  
 Linnoila, M. 20:229, 21:161  
 Loosen, P.T. 21:307  
 Lousberg, H. 20:87  
 Lykouras, L. 21:277  
 Lynch, J.J. 22:69  
 Macciardi, F. 21:293  
 MacLean, A. 22:149  
 Maddock, R.J. 22:29  
 Maes, M. 21:323  
 Maggioni, M. 20:19  
 Magnani, A. 20:207  
 Maguire, K.P. 22:213  
 Magyar, K. 21:355  
 Maislin, G. 20:325  
 Maj, M. 21:137  
 Malliaras, D. 21:277  
 Mallinger, A.G. 22:49  
 Mandal, M.K. 20:317  
 Marangos, P.J. 21:247  
 Marder, L.R. 20:215  
 Marder, S.R. 22:283  
 Marinelli, D.L. 21:189  
 Markianos, M. 20:221  
 Markowitz, J.S. 21:9  
 Marnela, K.M. 20:337  
 Martin, J.V. 21:89  
 Martin, P. 21:267  
 Masuda, Y. 21:49  
 Matsushita, M. 21:285, 22:81  
 Matussek, N. 21:85  
 Maylath, E. 22:221  
 Mazziotta, J.C. 21:237  
 McAllister, D.A. 21:63  
 McAmis, W. 21:43  
 McCauley, R.B. 22:37  
 McGrath, P.J. 21:9  
 McIntyre, I.M. 22:43  
 Melia, E. 20:207  
 Meltzer, H.Y. 22:99  
 Mendelson, W.B. 21:89  
 Meyer, J.S. 20:129  
 Miller, M.M. 20:143  
 Milton, J. 21:89  
 Mintz, M. 22:311  
 Miyauchi, T. 21:285  
 Mohs, R.C. 20:307  
 Moldin, S.O. 22:159  
 Morris, J.C. 21:55  
 Moscovich, D. 21:221  
 Moses, J.A., Jr. 22:29  
 Müller, E.E. 20:19  
 Müller-Oerlinghausen, B. 20:117  
 Murchison, A. 22:29  
 Mykytyn, V.V. 20:307  
 Nakagawara, M. 21:85, 21:229  
 Nasrallah, H.A. 21:303, 22:229  
 Naukkarinen, H. 21:151  
 Nemes, Z.C. 20:313  
 Nerozzi, D. 20:207  
 Nomura, Y. 21:285  
 Norman, T.R. 20:199, 22:43  
 Nurnberger, J.I., Jr. 22:141  
 Ohno, S. 21:285, 22:81  
 Orsulak, P.J. 20:183  
 Oxenkrug, G.F. 22:37  
 Palkovits, M. 21:355  
 Pandey, G.N. 22:265  
 Panerai, A.E. 20:19  
 Papart, P. 22:193  
 Patlak, C.S. 20:165  
 Paul, S.M. 21:23  
 Peabody, C.A. 21:1, 22:21  
 Perel, J.M. 21:111  
 Perri, M.G. 21:63  
 Pettigrew, K.D. 20:165  
 Phelps, M.E. 21:237

Pickar, D. 20:229, 21:161, 22:91  
 Pirozzi, R. 21:137  
 Platt, S. 20:307  
 Plutchik, R. 22:243  
 Pohl, R. 21:359, 22:37, 22:263  
 Post, R.M. 21:71, 22:11  
 Prabucki, K. 20:285  
 Prasad, A. 22:111  
 Quitkin, F.M. 21:9  
 Rabkin, J.G. 21:9  
 Rai, A. 20:317  
 Rainey, J.M. 21:359, 22:37  
 Raisys, V. 20:13  
 Rampling, R.P. 22:111  
 Rauscher, F.P. 21:63  
 Raz, N. 22:91  
 Raz, S. 22:91  
 Regier, D.A. 20:165  
 Reynolds, C.F. III 21:95, 21:111  
 Rimon, R. 21:151  
 Robbins, D.R. 20:275  
 Robinson, D. 21:257  
 Rosenberg, S. 20:57  
 Rosenthal, N.E. 22:1  
 Roth, W.T. 22:29  
 Rothschild, A.J. 20:143, 20:155  
 Rotrosen, J. 21:185  
 Rotter, A. 22:1  
 Roy, A. 20:229, 21:161  
 Roy-Byrne, P.P. 21:71  
 Rubenstein, K. 22:257  
 Rubin, E.H. 21:55  
 Rubinow, D.R. 22:11  
 Russell, V.A. 20:239, 22:127  
 Ryan, J. 20:79  
 Sacchetti, E. 21:293  
 Sack, D.A. 21:89  
 Sakellariou, G. 20:221  
 Salem, N., Jr. 21:247  
 Sali, L. 20:19  
 Salminen, K. 21:151  
 Salvati, A. 21:137  
 Sandler, M. 22:111  
 Sato, C. 21:285  
 Sattin, A. 21:63  
 Schatzberg, A.F. 20:143, 20:155  
 Schildkraut, J.J. 20:155  
 Schlemmer, R.F., Jr. 20:249  
 Schmidt, H. 20:189  
 Schweitzer, J. 21:185  
 Secunda, S. 20:1  
 Selin, C.E. 21:237  
 Sershen, H. 20:313  
 Sharpless, N. 20:79  
 Shelton, S. 22:117  
 Sherwood, P. 22:263  
 Shima, S. 21:49  
 Shimogawa, S. 21:229  
 Siever, L.J. 22:257  
 Sigal, M. 22:311  
 Simmons-Alling, S. 22:141  
 Simon, P. 21:267  
 Sitaram, N. 22:261  
 Skwerer, R.G. 22:1  
 Smeraldi, E. 21:293  
 Smith, R.C. 20:33  
 Soubrie, P. 21:267  
 Spoor, J. 21:151  
 Stack, J.A. 21:95, 21:111  
 Starace, F. 21:137  
 Stefanis, C. 21:277  
 Steiger, A. 20:177  
 Steinberg, J.L. 21:257  
 Steinman, R. 22:341  
 Steketee, G. 21:123  
 Stenman, U.-H. 21:151  
 Stewart, J.W. 21:9  
 Stieglitz, R.-D. 20:117  
 Storandt, M. 21:55  
 Sunderland, T. 20:299  
 Surridge-David, M. 22:149  
 Suy, E. 21:323  
 Swann, A.C. 20:1  
 Sweeney, D.R. 20:261  
 Takahashi, R. 21:229  
 Takazu, O. 21:285, 22:81  
 Taljaard, J.J.F. 20:239, 22:127  
 Tariot, P. 22:117  
 Taylor, M.A. 20:57  
 Tekes, K. 21:355  
 Thase, M.E. 22:49  
 Thiemann, S. 20:47  
 Thienemann, M. 22:117  
 Tiller, J.W.G. 22:213  
 Timsit-Berthier, M. 22:193  
 Tollefson, G.D. 20:183  
 Tomer, R. 22:311  
 Tóthfalusi, L. 21:355  
 Tsichlakis, N. 20:221  
 Tsukomo, T. 21:49  
 Turkheimer, E. 22:91  
 Turner, T.H. 22:207  
 Uhde, T.W. 21:71, 21:247, 22:11  
 Ulrich, G. 20:117  
 Ur, E. 22:207

Valente, A. 21:137  
van den Hout, M.A. 20:87  
van der Molen, G.M. 20:87  
van Praag, H.M. 22:243  
Vassilopoulos, D. 21:277  
Veith, R.C. 21:313  
Villacres, E.C. 21:313  
Vita, A. 21:293  
Voeks, S.K. 21:199  
Volavka, J. 20:313  
von Frenckell, R. 22:193  
von Knorring, L. 22:179  
Voulgari, A. 21:277

Wagman, A.M.I. 22:319  
Wagner, R. 21:89  
Walker, R.F. 22:61  
Warner, M.D. 22:21  
Watanabe, A. 21:229  
Wehr, T.A. 21:89  
Weiler, S. 22:117  
Weinberger, D.R. 20:337, 22:91  
Wetterberg, L. 22:179

Whiteford, H.A. 21:1, 22:21  
Wiedemann, K. 20:83  
Wilcox, J.A. 21:303  
Wilkinson, C.W. 21:313  
Winokur, A. 20:325, 21:189  
Wirz-Justice, A. 21:181  
Witzke, W. 21:85  
Wolfe, N. 20:107  
Woods, D.J. 20:215  
Wyatt, R.J. 22:291

Yamaguchi, T. 22:81  
Yehuda, R. 20:129  
Yeragani, V.K. 21:359, 22:37, 22:263  
Yokoi, S. 21:285, 22:81  
Yoshimoto, S. 21:229  
Yuwiler, A. 22:283

Zeevi, S. 21:221  
Zimmer, B. 21:111  
Zimmerman, M. 20:265  
Zureick, J.L. 22:99  
Zwicker, A.P. 21:337



## Subject Index for 1987

Adenosine  
  caffeine in plasma, anxiety, 21:247

Adenylate cyclase  
  lithium, platelet, 21:221

$\alpha_2$ -Adrenoceptor  
  affective disorder, platelet, 22:127  
  affective illness, yohimbine in platelets, 20:107  
  panic disorder, rauwolscine binding, 22:43

$\beta$ -Adrenoceptor  
  affective disorder, lymphocyte binding, 20:239  
  affective disorder, platelet, 22:127  
  leukocyte membrane, cyanopindolol, 22:265  
  schizophrenia, affective disorders, 22:265

Adrenocorticotrophic hormone  
  cortisol, affective illness, 20:325, 22:117  
  lactate induced panic, 21:23

Affective disorder  
  adrenal gland volume, computed tomography, 21:189  
   $\alpha_2$ -adrenoceptor, platelets, 20:107, 22:127  
   $\beta$ -adrenoceptor binding, dexamethasone suppression test, 22:265  
   $\beta$ -adrenoceptor binding, severity, 20:239, 22:127  
  adrenocorticotrophic hormone, dexamethasone suppression, 20:235, 22:117  
  amino acids in serum, dexamethasone suppression test, 21:323  
  apomorphine, growth hormone, 22:193  
  arachidonic acid, platelet membrane phospholipid incorporation, 22:275  
  arecoline infusion, sleep, 22:261  
  bipolar disorder, growth hormone releasing factor, 22:141  
  bipolar disorder, growth hormone response to clonidine, 22:193  
  bipolar disorder, sodium transport, 22:49  
  bipolar/unipolar, Minnesota Multiphasic Personality Inventory, 22:159  
  bipolar/unipolar, norepinephrine, 21:161  
  bipolar/unipolar, panic attack incidence, 20:183  
  bipolar/unipolar, positron emission tomography, 22:81  
  blood pressure, clonidine and apomorphine response, 22:193

Affective disorder (cont.)  
  blood pressure, endogenous subtype, 21:85  
  calcium in serum, anxiety, 22:29  
  carbamazepine, family history, 21:71  
  carbamazepine, sleep deprivation, 22:11  
  catecholamines, dexamethasone, 20:143, 22:21, 22:127  
  circadian rhythm, plasma 3-methoxy-4-hydroxyphenylglycol, 20:79  
  clonidine, growth hormone, 22:193  
  corticotropin releasing hormone, affective illness, 20:229  
  cortisol, catecholamines, 20:143, 22:21, 22:127  
  cortisol, electroconvulsive therapy and naloxone, 22:207  
  cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127  
  cortisol, naloxone effect, 22:207  
  cortisol response to adrenocorticotrophic hormone, 20:235, 22:117  
  cortisol, serum amino acids, 21:323  
  delusional depression, family study, 21:277  
  dementia, antidepressants, 21:111  
  depression assessment, comparison of five self-report scales, 22:243  
  depression, Plutchik-van Praag self-report scale, 22:243  
  dexamethasone, cortisol, 20:143, 22:21, 22:117  
  dexamethasone,  $\beta$ -endorphin, 21:151  
  dexamethasone in plasma, cortisol suppression, 20:83  
  dexamethasone suppression test,  $\beta$ -adrenoceptor binding, 22:P\$  
  dexamethasone suppression test, adrenocorticotrophic hormone, 22:117  
  dexamethasone suppression test, melancholic subgroups, 20:235  
  dexamethasone suppression test, norepinephrine, 21:161  
  dexamethasone suppression test, serum amino acids, 21:323  
  dexamethasone suppression, thyroid stimulating hormone, 22:21, 22:127  
  dexamethasone suppression, urinary catecholamines, 20:229  
  dopamine in plasma, psychotic depression, 20:143

**Affective disorder (cont.)**

electroconvulsive therapy,  
carbamazepine, 22:11  
electroconvulsive therapy frequency,  
21:63  
electroconvulsive therapy, naloxone  
neuroendocrine effect, 22:207  
electroconvulsive therapy, thyroid-  
stimulating hormone, 20:207  
emotional blunting, factor analytic study,  
20:57  
 $\beta$ -endorphin, dexamethasone, 21:151  
familial subtypes, 3-methoxy-4-hydroxy-  
phenylglycol, 22:117  
family history, carbamazepine response,  
21:71  
fenfluramine response, prolactin 22:257  
frontal lobe, positron emission tomo-  
graphy, 22:81  
generalized anxiety disorder, mothers'  
illness, 20:285  
glucose in serum, anxiety, 22:29  
growth hormone, clonidine response,  
22:193  
growth hormone, electroconvulsive  
therapy and naloxone, 22:207  
growth hormone releasing factor,  
lithium, 22:141  
head trauma, bipolar/depressive 21:303  
homovanillic acid, thyroid-stimulating  
hormone, 22:21  
hyperventilation, serum phosphate, 22:29  
hypothyroidism, depressive symptoms,  
21:199  
imipramine binding, platelet, 21:33  
immune cell function, natural killer cell  
activity, 20:181  
light therapy, mood effect, 22:1  
lithium distribution, mania, 20:1  
lithium effect, sodium transport, 22:49  
lithium, growth hormone releasing  
factor, 22:141  
magnetic resonance imaging, bipolars,  
21:357  
mania, growth hormone response to  
clonidine and apomorphine, 22:193  
membrane potential, lithium effect, 22:49  
3-methoxy-4-hydroxyphenylglycol,  
circadian rhythm, 20:79  
3-methoxy-4-hydroxyphenylglycol, panic  
attacks, 20:183  
3-methoxy-4-hydroxyphenylglycol,  
thyroid-stimulating hormone, 22:21,  
22:127

**Affective disorder (cont.)**

Minnesota Multiphasic Personality  
Inventory, 22:159  
monoamine metabolites, red blood  
cell/lithium ratio, 20:1  
monoamine oxidase inhibitors, social  
behavior, 22:89  
naloxone, electroconvulsive therapy, 22:207  
norepinephrine, cold challenge, 21:161  
norepinephrine in plasma, cortisol, 22:117  
opioids, electroconvulsive therapy, 22:207  
panic disorders, adolescents, 20:275  
phosphate serum levels, anxiety, 22:29  
phospholipids, arachidonic acid  
incorporation, 22:275  
placebo response, antidepressants, 21:9  
positron emission tomography,  
bipolar/unipolar, 22:81  
prolactin, electroconvulsive therapy and  
naloxone, 22:207  
prolactin response, fenfluramine, 22:257  
psychotic depression, plasma dopamine,  
20:143  
secondary depression, thyroid-stimulating  
hormone, 22:21  
self-report scales, development and  
methodology, 22:243  
serotonin reuptake inhibitors, fenfluramine,  
22:257  
severity,  $\beta$ -adrenoceptor binding, 20:239  
severity, dopamine in plasma, 20:143  
severity, rapid eye movement sleep,  
20:189  
severity, thyroid-stimulating hormone, 22:21  
sleep, arecoline infusion, 22:261  
sleep deprivation, carbamazepine, 22:11  
sleep deprivation, older endogenous  
depression, 21:95  
sleep, frequency analysis of electro-  
encephalogram, 21:89  
sleep variables, polysomnography 20:189  
sodium transport, lithium effect, 22:49  
suicidal thoughts, 5-hydroxy-indoleacetic  
acid, 21:1  
suicide, delusional depression, 21:277  
thyroid-stimulating hormone, depressive  
symptoms, 21:199  
thyroid-stimulating hormone, electro-  
convulsive therapy, 20:207  
thyroid-stimulating hormone, 3-methoxy-  
4-hydroxyphenylglycol, 22:21

**Age**

$\alpha_2$ -adrenoceptors in platelets, affective  
illness 20:107

**Age (cont.)**

- anxiety, caffeine in plasma, 21:247
- cortisol, affective illness, 20:143, 20:155
- dopamine in plasma, affective illness, 20:143
- dopamine- $\beta$ -hydroxylase, 20:221
- melatonin, chronic pain, 22:179

**Aggressive behavior**

- amphetamine, laboratory response, 21:257

**Alcoholism**

- perceptual aberration scale, monoamine oxidase, 20:129
- reaction time, evoked potentials, 22:B\$
- thyroid-stimulating hormone, secondary depression, 22:21

**Alzheimer's dementia**

- antidepressant treatment, 21:111
- personality change, factor structure, 21:55

**Amino acids**

- brains post-mortem, schizophrenia, 22:291
- dexamethasone suppression test, affective disorder, 21:323
- schizophrenia, levels in cerebrospinal fluid, 20:337

**Amphetamine**

- aggressive behavior, button press response, 21:257
- psychosis induction, 5-hydroxy-tryptophan, 22:283

**Anorexia nervosa**

- clonidine, growth hormone response, 20:19
- clonidine treatment, 3-methoxy-4-hydroxyphenylglycol, 20:249
- $\beta$ -endorphin, desmethylimipramine response, 20:19
- rapid eye movement sleep, concurrent depression, 20:189

**Antidepressants**

- carbamazepine response, sleep deprivation and electroconvulsive therapy, 22:11
- dementia treatment in elderly, 21:111
- lactate panic, hyperventilation 21:205
- monoamine oxidase inhibitors, social behavior, 22:89
- placebo response, 21:9
- sleep deprivation, prolactin and growth hormone, 21:337
- triiodothyronine potentiation, learned helplessness, 21:267

**Apomorphine**

- growth hormone response, affective disorder, 22:193

**Arachidonic acid**

- membrane phospholipids, schizophrenia, 22:275

**Arecoline**

- rapid eye movement sleep, affective illness, 22:261

**Attention**

- electroencephalogram, lithium, 20:117
- negative symptoms, schizophrenia, 20:47

**Blood pressure**

- anorexia nervosa, clonidine, 20:19
- clonidine, anorexia nervosa, 20:249
- clonidine and apomorphine response, affective disorder, 22:193

**endogenous/nonendogenous diagnosis, 21:85**

- lactate infusion, bulimia, 21:213
- lactate infusion, panic disorder, 21:169, 22:263
- mitral valve prolapse, panic disorder, 20:13
- panic disorder, plasma norepinephrine, 21:313
- schizophrenia, speaking, 22:69

**Blood-brain barrier**

- dynamic computed tomography, schizophrenia, 22:229

**Borderline personality disorder**

- prolactin, cortisol and  $T_3$ , 21:307
- thyroid-stimulating hormone, haloperidol treatment, 21:307

**Brain structure**

- magnetic resonance imaging, schizophrenia, 20:33

**Brofaremine**

- rapid eye movement sleep, 20:177

**Bromocriptine**

- cocaine craving reversal, 20:261

**Bulimia. *See also* Anorexia nervosa**

- lactate induced panic, 21:213
- sleep recording, depression type, 20:189

**Caffeine**

- adenosine in plasma, anxiety, 21:247

**Calcium**

- affective disorder, serum levels, 22:29

**Cancer**

- monoamine oxidase in platelets, depression, 22:111

**Carbamazepine**

- mania response, family history, 21:71
- response rate compared to sleep deprivation, 22:11

**Carbamazepine**  
 schizophrenia, clinical response, 22:D\$

**Carbidopa**  
 homovanillic acid, lack of effect, 21:185

**Carbon dioxide**  
 panic disorder, inhalation, 20:87

**Catecholamines**  
 corticotropin-releasing hormone, affective disorder, 20:229  
 depression severity, cerebrospinal fluid levels, 21:1  
 dexamethasone, affective illness, 20:143  
 growth hormone response to clonidine and apomorphine, 22:193  
 lithium treatment, red blood cell ratio, 20:1  
 monoamine oxidase, affective symptoms, 20:155  
 panic disorder, mitral valve prolapse, 20:13

**Childhood disorders**  
 generalized anxiety disorder, over-anxious disorder, 20:285  
 panic disorder, concurrent depression, 20:275

**Circadian rhythms**  
 light therapy, mood change, 22:1  
 3-methoxy-4-hydroxyphenylglycol, affective illness, 20:79  
 sleep phase shift, mood in normals, 22:149

**Circannual rhythm**  
 diurnal mood variation, 21:181  
 imipramine binding, affective disorder, 21:33  
 light therapy, seasonal affective disorder, 22:1  
 personality dimensions, 21:181  
 placebo response, antidepressants, 21:9

**Clonidine**  
 anorexia nervosa, growth hormone and desmethylimipramine, 20:19  
 anorexia nervosa, 3-methoxy-4-hydroxyphenylglycol, 20:249  
 growth hormone response, affective disorder, 22:193

**Cocaine**  
 bromocriptine reverses craving, 20:261

**Computed tomography**  
 adrenal gland volume, 21:189  
 blood-brain barrier, schizophrenia, 22:229  
 contrast material time-density curves, schizophrenia, 20:165  
 schizophrenia, third ventricle enlargement, 21:49

**Computed tomography (cont.)**  
 ventricular size, methodological review, 22:91

**Corticotropin releasing hormone**  
 norepinephrine, affective disorder, 20:229

**Cortisol**  
 $\beta$ -adrenoceptor binding, schizophrenia and affective disorder, 22:265  
 adrenocorticotrophic hormone effect, affective illness, 20:235, 22:117  
 affective illness, dexamethasone, 20:143, 20:155  
 amino acids in serum, affective illness, 21:323  
 anorexia nervosa, clonidine and desmethyl-imipramine, 20:19  
 borderline personality disorder, 21:307  
 $\beta$ -endorphin, dexamethasone, 21:151  
 lactate induced panic, 21:23  
 monoamine oxidase in platelet, 20:155  
 naloxone and electroconvulsive therapy, 22:207  
 norepinephrine, affective illness, 22:127

**Cyanopindolol**  
 leukocyte membrane binding, affective disorder and schizophrenia, 22:265

**Cyclic adenosine monophosphate**  
 lithium adenylate cyclase in platelet, 21:221

**Dementia**  
 antidepressant treatment in elderly, 21:111

**Desipramine**  
 anorexia nervosa, weight, 20:19  
 cortisol, clonidine, 20:19  
 growth hormone,  $\beta$ -endorphin, 20:19  
 sleep deprivation, prolactin and growth hormone, 21:337

**Dexamethasone**  
 adrenocorticotrophic hormone effect, cortisol, 20:235  
 cortisol suppression, plasma level, 20:83

**Dexamethasone suppression test**  
 $\beta$ -adrenoceptor binding, affective disorder, 20:239, 22:265  
 $\beta$ -adrenoceptor binding, schizophrenia, 22:265  
 adrenocorticotrophic hormone, affective illness, 22:117  
 amino acids in serum, affective disorder, 21:323  
 catecholamines in plasma, psychotic depression, 20:143  
 corticotropin-releasing hormone, norepinephrine, 20:229  
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 22:127

**Dexamethasone suppression test (cont.)**

- β*-endorphin and *β*-lipotropin, cortisol, 21:151
- family history of affective illness, 20:265
- norepinephrine, cold challenge, 21:161
- thyroid-stimulating hormone, affective illness, 22:21

**Diagnosis**

- Diagnostic Inventory Schedule for Children, 20:285
- generalized anxiety disorder, validity, 20:285
- Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159
- panic disorder and concurrent depression in adolescents, 20:275

**Dihydroalprenolol**

- lymphocyte binding, affective disorder, 20:239

**Dopamine**

- affective illness, dexamethasone, 20:143, 20:155
- Dopamine-*β*-hydroxylase schizophrenia, family study, 20:221

**Electroconvulsive therapy**

- carbamazepine, sleep deprivation, 22:11
- dementia, 21:111
- naloxone, growth hormone and prolactin, 22:207
- prolactin and thyroid-stimulating hormone, 20:207
- treatment frequency, 21:63

**Electroencephalogram**

- frequency analysis, sleep, 21:89
- lithium, normal controls, 20:117
- sleep, affective illness, 21:89
- ventricular enlargement, frequency analysis in schizophrenia, 21:137

**β-Endorphin**

- anorexia nervosa, clonidine, 20:19

**Epinephrine**

- affective illness, dexamethasone, 20:143, 20:155
- anxiety ratings, panic disorder, 21:313

**Evoked potentials**

- contingent negative variation, schizophrenia and alcoholism, 22:331
- neuroleptic side effects, hemispheric asymmetry, 22:311

**Eye movements**

- lateralization, schizophrenia, 20:215
- smooth pursuit, schizophrenia, 21:293

**Fenfluramine**

- prolactin response, affective disorder, 22:257

**Frontal lobe**

- amino acids, post-mortem brain in schizophrenia, 22:291
- blood-brain barrier permeability, hypofrontal pattern, 22:229
- glucose metabolic rate, affective disorder, 22:81

**Generalized anxiety disorder**

- diagnostic validity, family study, 20:285

**Genetics**

- delusional depression, multifactorial inheritance, 21:277
- dexamethasone suppression, family history of affective illness, 20:265
- dopamine-*β*-hydroxylase, schizophrenia, families, 20:221
- generalized anxiety disorder, mother's illness, 20:285
- human leukocyte antigens, schizophrenia, 20:69
- 3-methoxy-4-hydroxyphenylglycol, familial subtypes of affective illness, 22:117

**Glucose**

- phosphate serum level, affective illness, 22:29
- positron emission tomography, affective disorder, 22:81
- positron emission tomography, schizophrenia, 21:285
- positron emission tomography, sex differences in metabolic rate, 21:237

**Growth hormone**

- anorexia nervosa, clonidine and desmethyl-imipramine, 20:19
- clonidine and apomorphine response, affective disorder, 22:193
- naloxone and electroconvulsive therapy, 22:207
- sleep deprivation, desimipramine treatment, 21:337

**Growth hormone releasing factor**

- bipolar affective disorder, lithium effect, 22:141

**Heart rate**

- clonidine, anorexia nervosa, 20:249
- lactate infusion, panic disorder, 22:341
- mitral valve prolapse, panic disorder, 20:13
- panic disorder, plasma norepinephrine, 21:313
- schizophrenia, speaking, 22:69

- Heart rate (cont.)**
  - sleep infusion of arecoline, affective illness, 22:261
- Hemispheric asymmetry (see Laterality)**
- Homovanillic acid**
  - carbidopa effect, normal controls, 21:185
  - depression, cerebrospinal fluid level, 21:1
  - diet and physical activity, 20:307
  - lithium distribution, mania, 20:1
  - smoking, normal controls, 20:307
  - thyroid stimulating hormone, affective illness, 22:21
- Human leukocyte antigens**
  - schizophrenia, chromosome 6, 20:69
- 5-Hydroxyindoleacetic acid**
  - brains of suicides, 21:355
  - depression, cerebrospinal fluid level, 21:1
  - lithium distribution, mania, 20:1
- 5-Hydroxytryptamine**
  - brains of suicides, 21:355
- 5-Hydroxytryptophan**
  - amphetamine induced psychosis, schizophrenia, 22:283
- Imipramine**
  - obsessive-compulsive disorder treatment, 21:123
- Imipramine binding**
  - affective illness and panic disorder, 21:33
  - brains of suicides, platelet binding, 21:355
  - circannual variation, 21:33
- Immune function**
  - affective illness, natural killer cells, 20:181
- Isoproterenol**
  - blood pressure, panic disorder, 22:263
- Lactate**
  - adrenocorticotrophic hormone, cortisol, 21:23
  - antidepressants, panic, 21:205
  - blood pressure, panic disorder, 22:263
  - bulimia, anxiety, 21:213
  - gravity feed administration, 21:359
  - heart rate, panic disorder, 22:341
  - panic attacks, baseline blood pressure, 21:169
  - panic disorder, agoraphobia, 20:97
- Laterality**
  - brains of suicides, serotonergic function, 21:355
  - clockwise circling, schizophrenia, 20:215
  - evoked potentials, neuroleptic side effects, 22:311
- Learned helplessness**
  - triiodothyronine, antidepressant interaction, 21:267
- Life events**
  - schizophrenia, relapse off medication, 22:221
- Light**
  - treatment, depression change, 22:1
- $\beta$ -lipotropin**
  - dexamethasone, cortisol, 21:151
- Lithium**
  - adenylate cyclase, platelet, 21:221
  - electroencephalogram, normals, 20:117
  - growth hormone releasing factor, bipolars, 22:141
  - neuroleptic levels in brain and plasma, 20:313
- Lithium (cont.)**
  - red blood cell ratio, monoamine metabolites, 20:1
  - sodium transport, red blood cell, 22:49
- Magnetic resonance imaging**
  - bipolar affective illness, subcortical signal hyperintensities, 21:357
  - schizophrenia, ventricular size and image intensity, 20:33
- Melatonin**
  - pain syndromes, depressive symptoms, 22:179
- Membrane transport**
  - sodium transport, bipolar affective disorder, 22:49
- Memory**
  - electroconvulsive therapy, 21:63
- Metanephrine**
  - lithium distribution, mania, 20:1
- 3-Methoxy-4-hydroxyphenylglycol**
  - anorexia nervosa, clonidine treatment, 20:249
  - circadian rhythm, affective illness, 20:79
  - corticotropin-releasing hormone, dexamethasone suppression test, 20:229
- cortisol, thyroid stimulating hormone, 22:127**
  - depression, cerebrospinal fluid level, 21:1
  - lithium distribution, mania, 20:1
  - mitral valve prolapse, panic disorder, 20:13
  - panic attacks, depressed patients, 20:183
  - red blood cell/lithium ratio, mania, 20:1
  - thyroid-stimulating hormone, affective illness, 22:21
- Mitral valve prolapse**
  - panic disorder, catecholamines, 20:13
- Moclobemide**
  - tyramine-pressor response, clinical response, 22:213

**Monoamine oxidase**  
 cancer, depression, 22:111  
**Hamilton Rating Scale for Depression**,  
 items, 20:155  
 mitral valve prolapse, panic disorder,  
 20:13  
 panic disorder, platelets, 22:37  
 paranoia, schizophrenia, 22:99  
 psychosis proneness, college students,  
 20:129  
 psychotic depression, plasma cate-  
 cholamines, 20:155  
 race, gender, 22:99  
 schizophrenia, auditory hallucinations,  
 22:99  
 schizophrenia,  $\beta$ -phenylethylamine,  
 21:229  
 smoking, normals, 20:199  
**Monoamine oxidase inhibition**  
 rapid eye movement sleep, 20:177  
 social behavior, affective illness, 22:89  
 tyramine-pressor response, 22:213  
**Naloxone**  
 electroconvulsive therapy, growth  
 hormone and prolactin, 22:207  
**Neuroleptics**  
 brain distribution, rat, 20:299  
 brain and plasma levels, lithium effect,  
 20:313  
 carbamazepine combined with  
 haloperidol, 22:303  
 dopamine- $\beta$ -hydroxylase, dose, 20:221  
 $\beta$ -endorphin, dexamethasone, 21:151  
 evoked potentials, lateralized side  
 effects, 22:311  
 lateralized side effects, evoked potential  
 hemispheric asymmetry, 22:311  
 life events, relapse, 22:221  
 thyroid-stimulating hormone, borderline  
 personality disorder, 21:307  
**Norepinephrine**  
 affective illness, dexamethasone, 20:143,  
 20:155  
 cold challenge, affective illness, 21:161  
 corticotropin releasing hormone,  
 affective illness, 20:229  
 cortisol, affective illness, 22:127  
 isotope dilution kinetics, 21:313  
 lithium distribution, mania, 20:1  
**Normal values**  
 adrenal gland volume, CT scan, 21:189  
 amino acids, brains, 22:291  
 arachidonic acid incorporation, platelet  
 membrane phospholipids, 22:275  
**Normal values (cont.)**  
 cortisol, dexamethasone, 20:143  
 cortisol, plasma, 22:127  
 cortisol, plasma, clonidine response,  
 20:19  
 dexamethasone suppression test, 20:265  
 dopamine, plasma, dexamethasone,  
 20:143  
 electroencephalogram, lithium, 20:117  
 $\beta$ -endorphin,  $\beta$ -lipotropin, plasma,  
 21:151  
 $\beta$ -endorphin, plasma, clonidine  
 stimulation, 20:19  
 epinephrine, dexamethasone, 20:143  
 growth hormone, clonidine response, 20:19  
 growth hormone releasing factor,  
 cerebrospinal fluid, 22:141  
 imipramine binding, platelet, 21:33  
 melatonin, serum and urine, 22:179  
 3-methoxy-4-hydroxyphenylglycol, plasma,  
 22:127  
 monoamine oxidase, platelets, 20:129,  
 22:27, 22:99  
 norepinephrine, dexamethasone, 20:143  
 norepinephrine, plasma, 22:127  
 rauwolscine binding in platelet, 22:43  
 sleep, EEG frequency analysis, 21:89  
 smooth pursuit eye movements, 21:293  
 ventricular size, magnetic resonance  
 imaging, 20:33  
 yohimbine binding, platelet, 20:107  
**Normetanephrine**  
 corticotropin-releasing hormone, affective  
 illness, 20:229  
 lithium distribution, mania, 20:1  
**Obsessive-compulsive disorder**  
 birth order, family size 21:347  
 imipramine response, 21:123  
**Opioids**  
 naloxone, electroconvulsive therapy,  
 22:207  
**Outcome**  
 emotional blunting, treatment response,  
 20:57  
 red blood cell/lithium ratio, 20:1  
**Pain syndromes**  
 melatonin, neurogenic pain syndrome,  
 22:179  
**Panic disorder**  
 adolescents, concurrent depressive  
 disorders, 20:275  
 $\alpha_2$ -adrenoceptor binding, platelet, 22:43  
 adrenocorticotrophic hormone, lactate  
 administration, 21:23

**Panic disorder (cont.)**

- blood pressure, lactate panic, 21:169, 22:263
- catecholamines, cardiovascular measures, 20:13
- CO<sub>2</sub> inhalation, panic provocation, 20:87
- cortisol, lactate effect, 21:23
- epinephrine, anxiety ratings, 21:313
- heart rate, lactate infusion, 22:341
- lactate, blood pressure, 22:263
- lactate infusion, 20:97
- imipramine binding, platelet, 21:33
- 3-methoxy-4-hydroxyphenylglycol, depressed patients, 20:183
- mitral valve prolapse, platelet monoamine oxidase, 20:13
- monoamine oxidase in platelets, 22:37
- norepinephrine kinetics, 21:313
- psychoactive medication, lactate panic, 21:205

**Phenylacetic acid**

- schizophrenia, monoamine oxidase, 21:229

**β-Phenylethylamine**

- schizophrenia, monoamine oxidase, 21:229

**Phosphate**

- affective disorder, serum levels, 22:29

**Phospholipids**

- arachidonic acid incorporation, platelet membranes, 22:275

**Platelets**

- adenylate cyclase, lithium, 21:221
- arachidonic acid incorporation, membrane phospholipids, 22:275
- imipramine binding, affective illness, 21:33
- monoamine oxidase, mitral valve prolapse, 20:13
- monoamine oxidase, panic disorder, 22:37
- monoamine oxidase, psychosis proneness, 20:129
- monoamine oxidase, psychotic depression, 20:155
- monoamine oxidase, schizophrenia, 21:229
- rauwolscine binding, panic disorder, 22:43
- serotonin uptake, rat strain differences, 22:61
- yohimbine binding, affective disorder, 20:107

**Positron emission tomography**

- bipolar and unipolar affective disorder, 22:81

**Positron emission tomography (cont.)**

- schizophrenia, frontal and parietal lobes, 21:285
- sex differences, glucose, metabolic rate, 21:237

**Prolactin**

- borderline personality disorder, haloperidol, 21:307
- electroconvulsive therapy and thyroid-stimulating hormone, 20:207
- fenfluramine response, affective disorder, 22:257
- naloxone, electroconvulsive therapy, 22:207
- sleep deprivation, desipramine treatment, 21:337

**Race**

- schizophrenia, auditory hallucinations, 22:99

**Red blood cell**

- lithium ratio, monoamine metabolites, 20:1

**Rapid eye movement sleep (see Sleep)**

**Rauwolscine**

- panic disorder, platelet binding, 22:43

**Reaction time**

- cross-over effect, schizophrenia, 22:331

**Red blood cell**

- sodium transport, lithium effect, 22:49

**Scales**

- Acute Panic Inventory, lactate infusions, 20:97, 21:169, 21:205
- Beck Depression Inventory, β-adrenoceptor, 20:239
- Beck Depression Inventory, correlation with four self-report scales, 22:243
- Beck Depression Inventory, obsessive-compulsive disorder, 21:123
- Blessed Dementia, Alzheimer's dementia, 21:55
- Blessed Dementia, antidepressant response, 21:111
- Brief Psychiatric Rating Scale, carbamazepine response, 22:303
- Brief Psychiatric Rating Scale, life events, 22:221
- Brief Psychiatric Rating Scale, negative symptoms, 20:47

**Center for Epidemiological Studies—Depression Questionnaire**

- correlation with four self-report scales, 22:243

**Compulsive Activity Checklist**

- imipramine response, 21:123

**Emotional Blunting Scale**

- schizophrenia and affective illness, 20:57

**Folstein Mini-Mental**

- antidepressants in elderly, 21:111

**Geriatric Depression Scale**

- hypothyroidism, 21:199

## Scales (cont.)

Hamilton Rating Scale for Anxiety, platelet monoamine oxidase, 22:111

Hamilton Rating Scale for Depression, adolescent/panic disorder, 20:275

Hamilton Rating Scale for Depression,  $\alpha_2$ -adrenoceptor affinity, 20:107

Hamilton Rating Scale for Depression,  $\beta$ -adrenoceptor binding, 20:239

Hamilton Rating Scale for Depression, cerebrospinal fluid amine metabolites, 21:1

Hamilton Rating Scale for Depression, electroconvulsive therapy, 20:207

Hamilton Rating Scale for Depression, light treatment, 22:1

Hamilton Rating Scale for Depression, monoamine oxidase 20:155

Hamilton Rating Scale for Depression, phosphate and calcium, 22:29

Hamilton Rating Scale for Depression, rapid eye movement sleep, 20:189

Hamilton Rating Scale for Depression, sleep deprivation, 21:95

Hamilton Rating Scale for Depression, thyroid-stimulating hormone, 22:21

Inpatient Multidimensional Rating Scale, carbamazepine response, 22:303

Manic Diagnostic and Severity Scale, lithium, 20:1

Maudsley Obsessional-Compulsive Inventory, 21:123

Minnesota Multiphasic Personality Inventory, diagnostic validation, 22:159

Minnesota Multiphasic Personality Inventory, serum phosphate, 22:29

Minnesota Multiphasic Personality Inventory D Scale, correlation with four self-report scales, 22:243

Montgomery-Asberg Depression Scale, platelet monoamine oxidase, 22:111

Perceptual Aberration Scale, platelet monoamine oxidase, 20:129

Physical Anhedonia Scale, platelet monoamine oxidase, 20:129

Plutchik-van Praag Self-Report Depression Scale, criteria for depression, 22:293

Profile of Mood States, sleep deprivation, 21:95

Scale for Assessment of Negative Symptoms, redundant measures, 20:47

## Scales (cont.)

Spielberger Anxiety Rating, bulimia, 21:213

Spielberger Anxiety Rating, imipramine response, 21:123

Spielberger Anxiety Rating, plasma caffeine, 21:247

Stanford Sleepiness Scale, sleep deprivation, 22:149

Subjective Units of Disturbance, anxiety, 20:87

Wechsler Adult Intelligence Scale, ventricular enlargement, 21:137

Wechsler Rating Scale for Depression, 20:19

Zung Depression Scale, anorexia nervosa, 20:19

Zung Depression Scale, comparison with four self-report scales, 22:243

Zung Anxiety Rating, plasma caffeine, 21:247

Schizophrenia

$\beta$ -adrenoceptor binding, dexamethasone suppression test, 22:265

affect in facial emotion, photo judgment, 20:317

amino acids, cerebrospinal fluid, 20:337

amino acids, post-mortem brain, 22:291

$\gamma$ -aminobutyric acid (GABA), post-mortem brain, 22:291

amphetamine induction of psychosis, 5-hydroxytryptophan, 22:283

auditory hallucinations, platelet-monoamine oxidase, 22:99

blood-brain barrier permeability, dynamic computed tomography, 22:229

blood pressure, speaking, 22:69

carbamazepine, clinical response, 22:303

computed tomography, blood-brain barrier permeability, 22:229

computed tomography, contrast material time density curves, 20:165

computed tomography, methodology, 22:91

contingent negative variation, reaction time, 22:331

cross-over effect, evoked potentials, 22:331

deficit syndrome, neuropsychological impairment, 22:319

dexamethasone suppression test,  $\beta$ -adrenoceptor binding, 22:265

dopamine- $\beta$ -hydroxylase, family studies, 20:221

educational level, deficit syndrome, 22:319

electroconvulsive therapy, thyroid-stimulating hormone, 20:207

**Schizophrenia (cont.)**

- electroencephalogram, ventricular enlargement, 21:137
- emotional blunting, factor analytic study, 20:57
- employment status, blood pressure, 22:69
- evoked potentials, hemispheric asymmetry, 22:311
- evoked potentials, reaction time, 22:331
- eye movements, lateralization, 20:215
- eye movements, ventricle size, 21:293
- facial emotion judgments, 20:317
- fibroblasts, growth and response to toxic oxygen metabolites, 21:43
- frontal lobe, blood-brain barrier permeability, 22:229
- frontal white matter, magnetic resonance image, 20:33
- hallucinations, platelet monoamine oxidase, 22:99
- head trauma history, 21:303
- heart rate, speaking, 22:69
- high risk sample, Minnesota Multiphasic Personality Inventory, 22:159
- human leukocyte antigens, chromosome 6, 20:69
- 5-hydroxytryptophan, amphetamine induction of psychosis, 22:283
- hypofrontality, dynamic computed tomography, 22:229
- hypofrontality, positron emission tomography, 21:285
- laterality, blood-brain barrier permeability, 22:229
- laterality, clockwise circling, 20:215
- lateralized neuroleptic side effects, evoked potentials, 22:311
- life events, relapse, 22:221
- Luria-Nebraska Neuropsychological Battery, ventricular enlargement, 21:137
- magnetic resonance imaging, image intensity, 20:33
- Minnesota Multiphasic Personality Inventory, diagnosis, 22:159
- monoamine oxidase in platelet, auditory hallucinations, 22:99
- monoamine oxidase in platelets, psychosis proneness, 20:129
- monoamine oxidase, urinary phenylethylamine, 21:229
- negative symptoms, neuropsychological impairment, 22:319
- negative symptom measurement, 20:47
- negative symptoms, ventricular enlargement, 21:137

**Schizophrenia (cont.)**

- neuroleptics, relapse and life events, 22:221
- neuropsychological impairment, deficit syndrome, 22:319
- paranoid type, phenylethylamine in urine, 21:229
- paranoid type, platelet monoamine oxidase, 22:99
- phenylacetic acid, platelet monoamine oxidase, 21:229
- phenylethylamine, platelet monoamine oxidase, 21:229
- positron emission tomography, 21:285
- prolactin, electroconvulsive therapy, 20:207
- race, platelet monoamine oxidase, 22:99
- reaction time cross-over effect, evoked potentials, 22:331
- relapse, life events, 22:221
- schizoaffective disorder diagnosis, high-risk sample, 22:159
- schizophreniform, arachidonic acid incorporation, 22:275
- serotonin, psychosis induction by amphetamine, 22:283
- sex differences, platelet monoamine oxidase, 22:99
- speaking, cardiovascular response, 22:69
- ventricular enlargement, smooth pursuit eye movements, 21:293
- ventricular enlargement, Wechsler Adult Intelligence Scale, 21:137
- ventricular size, 20:33, 21:49
- ventricular size, methodological review, 22:91
- tardive dyskinesia, evoked potentials, 22:311
- Seasonal affective disorder
- light treatment, mood change in normals, 22:1
- Serotonin
- amphetamine induced psychosis, 5-hydroxytryptophan, 22:283
- platelet uptake, methods and rat-strain differences, 22:61
- prolactin response to fenfluramine, affective disorder, 22:257
- Sex differences
- dopamine- $\beta$ -hydroxylase, schizophrenia, 20:221
- lactate response, panic disorder, 22:341
- glucose metabolic rate, positron emission tomography, 21:237
- melatonin, chronic pain, 22:179
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 20:13

**Sex differences (cont.)**

- monoamine oxidase in plasma, panic disorder, 20:13
- monoamine oxidase in platelets, panic disorder, 20:13
- monoamine oxidase, platelets, 20:129, 20:155, 20:199, 22:37, 22:99
- panic disorder, lactate response, 22:341

**Sleep**

- arecoline infusion, rapid eye movement sleep, 22:261
- carbamazepine response, 21:71, 22:11
- deprivation, carbamazepine effect, 22:11
- deprivation, desipramine effect, 21:337
- frequency analysis, affective illness, 21:89
- growth hormone, sleep deprivation, 21:337
- monoamine oxidase inhibition, rapid eye movements, 20:177
- phase shift, mood change in normals, 22:149
- prolactin, sleep deprivation, 21:337
- rapid eye movement sleep, acute sleep delay, 22:149
- sleep deprivation, endogenous depression, 21:95

**Sodium transport**

- lithium effect, bipolar affective disorder, 22:49

**Substance abuse**

- cocaine craving, bromocriptine, 20:261
- monoamine oxidase, perceptual aberration, 20:129
- paraphernalia, cocaine, 20:261

**Tachycardia (see Heart rate)**

**Tardive dyskinesia**

- lateralized neuroleptic side effects, evoked potentials, 22:311

**Thyroid-stimulating hormone**

- $\beta$ -adrenoceptor binding, dexamethasone suppression, 20:239

**Thyroid-stimulating hormone (cont.)**

- catecholamines, affective illness, 22:127
- depressive symptoms, nursing home, 21:199
- 3-methoxy-4-hydroxyphenylglycol, affective illness, 22:21
- neuroleptic effect, borderline personality disorder, 21:307
- prolactin and electroconvulsive therapy, 20:207

**Triiodothyronine**

- antidepressant potentiation, rat learned helplessness, 21:267
- borderline personality disorder, neuroleptic effect, 21:307

**Tyramine pressor response**

- monoamine oxidase inhibitor, moclobemide, 22:213

**Vanillylmandelic acid**

- corticotropin-releasing hormone, affective illness, 20:229

**Ventricular size**

- computed tomographic measurement, 22:91
- negative symptoms, neuropsychological scores, 21:137
- schizophrenia, magnetic resonance imaging, 20:33
- schizophrenia, third ventricle, 21:49
- smooth pursuit eye movements, schizophrenia, 21:293

**Weight**

- anorexia nervosa, desmethyl-imipramine, 20:19
- clonidine, anorexia nervosa, 20:249
- growth hormone-releasing factor, cerebrospinal fluid, 22:141

**Yohimbine**

- affective disorder, platelet binding, 20:107